Pharmacological Regulation in the USA and Pharmacokinetics Parameters of Firocoxib, a Highly Selective Cox-2, by Pain Management in Horses.
Authors: Rangel-Nava Ana, Ramírez-Uribe José Manuel, Recillas-Morales Sergio, Ibancovichi-Camarillo José Antonio, Venebra-Muñoz Arturo, Sánchez-Aparicio Pedro
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Firocoxib Pharmacology and Regulation in Equine Practice Firocoxib, a selective COX-2 inhibitor authorised by the FDA for pain management in horses, offers a valuable alternative to non-selective NSAIDs because of its improved safety profile when used at recommended doses and durations. This literature review synthesised regulatory approval status and pharmacokinetic data, establishing that the standard equine dose of 0.1 mg/kg can be administered as a single daily dose in oral paste form for up to 14 days, with plasma concentrations maintained for 7–14 days in tablet formulations—notably different kinetics from those observed in canine patients receiving identical pharmaceutical presentations. Critical to practice is understanding that firocoxib remains unauthorised for human use in most jurisdictions, and that species-specific pharmacokinetic variations demand careful adherence to established dosing protocols rather than extrapolation from other species. Knowledge of these parameters and regulatory constraints enables practitioners to employ firocoxib judiciously in chronic pain conditions, reducing the risk of inappropriate owner administration and inadvertent therapeutic failures or adverse effects that can result from misuse.
Read the full abstract on PubMed
Practical Takeaways
- •Firocoxib dosing in horses is 0.1 mg/kg; oral paste formulations can be used for up to 14 days, while tablets maintain effective concentrations for 7-14 days—knowing these parameters helps avoid overdosing and unnecessary prolonged treatment
- •COX-2 selectivity of firocoxib reduces gastrointestinal and renal side effects compared to traditional NSAIDs, making it safer for chronic pain management when dosing guidelines are followed
- •Never extrapolate dosing or pharmacokinetics between species; firocoxib dosing for horses differs significantly from dogs, so always use species-specific protocols to prevent adverse effects
Key Findings
- •Firocoxib is FDA-approved for pain treatment in horses at a dosage of 0.1 mg/kg as a single dose or up to 14 days in oral paste formulation
- •Firocoxib maintains therapeutic concentration for 7-14 days in oral tablet formulation
- •COX-2 selective NSAIDs like firocoxib produce fewer adverse effects than non-selective NSAIDs when administered at recommended doses within prescribed timeframes
- •Pharmacokinetic parameters of firocoxib differ between equine and canine species despite using identical pharmaceutical presentations